Higano CS - Search Results

1

Phenotypic heterogeneity of end-stage prostate carcinoma metastatic to bone.

Roudier MP, True LD, Higano CS, Vesselle H, Ellis W, Lange P, Vessella RL. Roudier MP, et al. Among authors: higano cs. Hum Pathol. 2003 Jul;34(7):646-53. doi: 10.1016/s0046-8177(03)00190-4. Hum Pathol. 2003. PMID: 12874759

2

Zoledronic acid exhibits inhibitory effects on osteoblastic and osteolytic metastases of prostate cancer.

Corey E, Brown LG, Quinn JE, Poot M, Roudier MP, Higano CS, Vessella RL. Corey E, et al. Among authors: higano cs. Clin Cancer Res. 2003 Jan;9(1):295-306. Clin Cancer Res. 2003. PMID: 12538482

3

Elevation of cytokine levels in cachectic patients with prostate carcinoma.

Pfitzenmaier J, Vessella R, Higano CS, Noteboom JL, Wallace D Jr, Corey E. Pfitzenmaier J, et al. Among authors: higano cs. Cancer. 2003 Mar 1;97(5):1211-6. doi: 10.1002/cncr.11178. Cancer. 2003. PMID: 12599227 Free article.

4

Expression of the human cachexia-associated protein (HCAP) in prostate cancer and in a prostate cancer animal model of cachexia.

Wang Z, Corey E, Hass GM, Higano CS, True LD, Wallace D Jr, Tisdale MJ, Vessella RL. Wang Z, et al. Among authors: higano cs. Int J Cancer. 2003 May 20;105(1):123-9. doi: 10.1002/ijc.11035. Int J Cancer. 2003. PMID: 12672042

5

Phase I study of weekly mitoxantrone and docetaxel before prostatectomy in patients with high-risk localized prostate cancer.

Beer TM, Garzotto M, Lowe BA, Ellis WJ, Montalto MA, Lange PH, Higano CS. Beer TM, et al. Among authors: higano cs. Clin Cancer Res. 2004 Feb 15;10(4):1306-11. doi: 10.1158/1078-0432.ccr-1021-03. Clin Cancer Res. 2004. PMID: 14977829 Clinical Trial.

6

Metastases of prostate cancer express estrogen receptor-beta.

Lai JS, Brown LG, True LD, Hawley SJ, Etzioni RB, Higano CS, Ho SM, Vessella RL, Corey E. Lai JS, et al. Among authors: higano cs. Urology. 2004 Oct;64(4):814-20. doi: 10.1016/j.urology.2004.05.036. Urology. 2004. PMID: 15491740

7

Molecular alterations in prostate carcinomas that associate with in vivo exposure to chemotherapy: identification of a cytoprotective mechanism involving growth differentiation factor 15.

Huang CY, Beer TM, Higano CS, True LD, Vessella R, Lange PH, Garzotto M, Nelson PS. Huang CY, et al. Among authors: higano cs. Clin Cancer Res. 2007 Oct 1;13(19):5825-33. doi: 10.1158/1078-0432.CCR-07-1037. Clin Cancer Res. 2007. PMID: 17908975 Clinical Trial.

8

Differential expression of angiogenesis associated genes in prostate cancer bone, liver and lymph node metastases.

Morrissey C, True LD, Roudier MP, Coleman IM, Hawley S, Nelson PS, Coleman R, Wang YC, Corey E, Lange PH, Higano CS, Vessella RL. Morrissey C, et al. Among authors: higano cs. Clin Exp Metastasis. 2008;25(4):377-88. doi: 10.1007/s10585-007-9116-4. Epub 2007 Oct 31. Clin Exp Metastasis. 2008. PMID: 17972146

9

Safety analysis of repeated high doses of samarium-153 lexidronam in men with hormone-naive prostate cancer metastatic to bone.

Higano CS, Quick DP, Bushnell D, Sartor O. Higano CS, et al. Clin Genitourin Cancer. 2008 Mar;6(1):40-5. doi: 10.3816/CGC.2008.n.007. Clin Genitourin Cancer. 2008. PMID: 18501082

10

Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth.

Montgomery RB, Mostaghel EA, Vessella R, Hess DL, Kalhorn TF, Higano CS, True LD, Nelson PS. Montgomery RB, et al. Among authors: higano cs. Cancer Res. 2008 Jun 1;68(11):4447-54. doi: 10.1158/0008-5472.CAN-08-0249. Cancer Res. 2008. PMID: 18519708 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

278 results

Search Page

Filters